Brief: FDA Accepts Supplemental New Drug Application For Arcutis’ Zoryve® (Roflumilast) Cream 0.3% For The Treatment Of Plaque Psoriasis In Children Ages 2 To 5
17/11/2025 13:15
Arcutis Biotherapeutics Inc ARQT.O: FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR ARCUTIS’ ZORYVE® (ROFLUMILAST) CREAM 0.3% FOR THE TREATMENT OF PLAQUE PSORIASIS IN CHILDREN AGES 2 TO 5 ARCUTIS BIOTHERAPEUTICS INC - FDA SETS PDUFA TARGET DATE FOR JUNE 29, 2026 Source text: ID:nGNX1F2Cl3 Further company coverage: ARQT.O
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4